The University of Chicago has dosed the first patient in an investigator-sponsored Phase 2a clinical trial evaluating an investigational drug in combination with Merck’s KEYTRUDA.® Evelo Biosciences, Inc (Nasdaq: EVLO) (Evelo) reports that its experimental EDP1503, an...